Overview of opioids in pain management
Opioids achieve analgesia by reducing transmission of nociceptive impulses (through effects at central nervous system mu-receptors) and modulating the descending inhibitory pathways from the brain. Some opioids (eg tramadol, tapentadol) also produce analgesia via nonopioid receptors. See Overview of opioids commonly used in pain management for prescribing considerations.
Opioid use is generally limited to acute pain or cancer pain. It is difficult to define a cohort of patients with chronic noncancer pain that would consistently respond to opioids.
- Using analgesics to manage acute pain
- The role of analgesics in chronic noncancer pain
- Procedural sedation and analgesia
- Cancer pain
- Principles of opioid use in palliative care.
Opioids can be administered via multiple routes; many factors influence the choice of administration route, see Routes of opioid administration for pain management.
In an opioid-naive patient, opioid doses are age-based. As people age, opioid dose requirements reduce because of increased brain sensitivity to opioid effects. Age-related physiological changes may also influence dose requirements (eg renal impairment, which may cause accumulation of active metabolites).
When prescribing opioids, potential harms must be considered alongside potential benefits. Harms include:
- neuroadaptive and physiological changes (eg opioid tolerance, physical dependence, opioid-induced hyperalgesia)—may occur after 7 to 10 days of use
- short- and long-term adverse effects
- misuse, abuse and diversion, and poisoning.
Change |
Description |
Clinical implications |
---|---|---|
opioid tolerance |
decrease in drug effect over time the ability to induce tolerance differs between opioids |
|
physical dependence |
abrupt opioid cessation, dose reduction or administration of a reversal agent will lead to a withdrawal syndrome; not the same as opioid-use disorder (addiction), but may be a component of it |
|
opioid-induced hyperalgesia |
increased sensitivity to pain, which may be diffuse and spread to locations other than the initial pain site mediated by opioid use rather than central sensitisation, but the underlying process is complex and not fully understood |
|
Note: NB1: Withdrawal symptoms include lacrimation; rhinorrhoea and sneezing; yawning; hot and cold flushes; sweating and piloerection; craving; anxiety; restlessness and irritability; disturbed sleep; gastrointestinal tract symptoms (eg anorexia, abdominal pain, nausea, vomiting, diarrhoea); muscle, bone and joint aches or pains; headache; muscle cramps; tremor. |